WO2003101392A3 - Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods - Google Patents
Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods Download PDFInfo
- Publication number
- WO2003101392A3 WO2003101392A3 PCT/US2003/017184 US0317184W WO03101392A3 WO 2003101392 A3 WO2003101392 A3 WO 2003101392A3 US 0317184 W US0317184 W US 0317184W WO 03101392 A3 WO03101392 A3 WO 03101392A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- conazole
- crystalline forms
- methods
- pharmaceutical compositions
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003243354A AU2003243354A1 (en) | 2002-05-31 | 2003-05-30 | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods |
EP03756321A EP1511490A4 (en) | 2002-05-31 | 2003-05-30 | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods |
JP2004508750A JP2005535602A (en) | 2002-05-31 | 2003-05-30 | Novel conazole crystal forms and related methods, pharmaceutical compositions and methods |
US10/926,842 US7446107B2 (en) | 2002-02-15 | 2004-08-26 | Crystalline forms of conazoles and methods of making and using the same |
US12/234,420 US20090088443A1 (en) | 2002-02-15 | 2008-09-19 | Novel crystalline forms of conazoles and methods of making and using the same |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38415202P | 2002-05-31 | 2002-05-31 | |
US60/384,152 | 2002-05-31 | ||
US43928203P | 2003-01-10 | 2003-01-10 | |
US60/439,282 | 2003-01-10 | ||
US44431503P | 2003-01-31 | 2003-01-31 | |
US60/444,315 | 2003-01-31 | ||
US46396203P | 2003-04-18 | 2003-04-18 | |
US60/463,962 | 2003-04-18 | ||
US10/449,307 US7078526B2 (en) | 2002-05-31 | 2003-05-30 | CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods |
US10/449,307 | 2003-05-30 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/027772 Continuation-In-Part WO2004078161A1 (en) | 2002-02-15 | 2003-09-04 | Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/449,307 Continuation-In-Part US7078526B2 (en) | 2002-02-15 | 2003-05-30 | CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods |
US10/926,842 Continuation-In-Part US7446107B2 (en) | 2002-02-15 | 2004-08-26 | Crystalline forms of conazoles and methods of making and using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003101392A2 WO2003101392A2 (en) | 2003-12-11 |
WO2003101392A3 true WO2003101392A3 (en) | 2004-04-08 |
Family
ID=29716372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/017184 WO2003101392A2 (en) | 2002-02-15 | 2003-05-30 | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods |
Country Status (5)
Country | Link |
---|---|
US (1) | US7078526B2 (en) |
EP (1) | EP1511490A4 (en) |
JP (1) | JP2005535602A (en) |
AU (1) | AU2003243354A1 (en) |
WO (1) | WO2003101392A2 (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US20090088443A1 (en) * | 2002-02-15 | 2009-04-02 | Julius Remenar | Novel crystalline forms of conazoles and methods of making and using the same |
US7078526B2 (en) * | 2002-05-31 | 2006-07-18 | Transform Pharmaceuticals, Inc. | CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods |
US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7446107B2 (en) | 2002-02-15 | 2008-11-04 | Transform Pharmaceuticals, Inc. | Crystalline forms of conazoles and methods of making and using the same |
AU2003213719A1 (en) * | 2002-03-01 | 2003-09-16 | Regents Of The University Of Michigan | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
US20070059356A1 (en) * | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
AU2003243699B2 (en) | 2002-06-21 | 2009-01-15 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
US8183290B2 (en) * | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
US7452555B2 (en) | 2003-01-21 | 2008-11-18 | S.S.C.I., Inc. | Cocrystallization |
KR101184797B1 (en) * | 2003-09-04 | 2012-09-20 | 세파론, 인코포레이티드 | Modafinil compositions |
US7566805B2 (en) * | 2003-09-04 | 2009-07-28 | Cephalon, Inc. | Modafinil compositions |
TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
JP2007516259A (en) * | 2003-12-09 | 2007-06-21 | メッドクリスタルフォームズ、エルエルシー | Method for preparing mixed phase co-crystal with activator |
US20090018202A1 (en) | 2004-02-06 | 2009-01-15 | Cephalon, Inc. | Modafinil compositions |
WO2005092884A1 (en) * | 2004-02-26 | 2005-10-06 | Transform Pharmaceuticals, Inc. | Novel crystalline forms of conazoles and methods of making and using the same |
EP2292585B1 (en) | 2004-03-12 | 2016-04-27 | Aptuit (West Lafayette), LLC | Screening for solid forms by ultrasound crystallization and cocrystallization using ultrasound |
WO2005118577A1 (en) * | 2004-04-22 | 2005-12-15 | Transform Pharmaceuticals, Inc. | Novel saperconazole crystalline forms and related processes, pharmaceutical compositions and methods |
JP5017103B2 (en) * | 2004-06-17 | 2012-09-05 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | Pharmaceutical co-crystal composition and related methods of use |
US20070099237A1 (en) * | 2005-10-31 | 2007-05-03 | The Regents Of The University Of Michigan | Reaction co-crystallization of molecular complexes or co-crystals |
WO2007092779A2 (en) * | 2006-02-03 | 2007-08-16 | Dr. Reddy's Laboratories Ltd. | Aripiprazole co-crystals |
US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
CA2662754A1 (en) * | 2006-08-22 | 2008-02-28 | Amgen Inc. | Sorbic acid analog co-crystals |
US9211286B2 (en) * | 2006-09-12 | 2015-12-15 | Curatek Pharmaceuticals Holding, Inc. | Terconazole composition and method |
JP5243963B2 (en) * | 2006-10-16 | 2013-07-24 | 協和発酵バイオ株式会社 | Glutathione crystals and process for producing the same |
CA2570949A1 (en) * | 2006-12-12 | 2008-06-12 | Apotex Pharmachem Inc. | Ibandronate sodium propylene glycol solvate and processes for the preparation thereof |
US7834195B2 (en) * | 2007-01-24 | 2010-11-16 | Apotex Pharmachem Inc. | Atorvastatin calcium propylene glycol solvates |
PE20090185A1 (en) * | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR |
EP2200613B1 (en) | 2007-09-21 | 2018-09-05 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
NZ589742A (en) | 2008-05-27 | 2012-06-29 | Univ Melbourne | Methods of treating mammals with eustachian tube dysfunctions with betahistine |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
PL3003038T3 (en) | 2013-06-07 | 2020-02-28 | The Scripps Research Institute | 2h-1,2,3-triazole derivatives as inhibitors of fibrosis |
US20150080567A1 (en) * | 2013-09-04 | 2015-03-19 | Nalas Engineering Services Inc. | Method to Produce and Scale-Up Cocrystals and Salts Via Resonant Acoustic Mixing |
CN103788077B (en) * | 2014-02-28 | 2016-03-09 | 上海现代哈森(商丘)药业有限公司 | A kind of synthetic method of hydrochloric acid Itraconazole |
CN107404878B (en) | 2014-12-10 | 2021-03-30 | 斯克利普斯研究所 | Small molecule inhibitors of fibrosis |
US9855248B2 (en) * | 2016-05-09 | 2018-01-02 | The Chinese University Of Hong Kong | Polymorph of itraconazole with improved pharmaceutical properties |
CN106478615B (en) * | 2016-08-31 | 2019-08-13 | 山东罗欣药业集团股份有限公司 | A kind of Itraconazole crystal-form compound and preparation method thereof |
EP3538079A4 (en) | 2016-11-28 | 2020-03-04 | Cellix Bio Private Limited | Compositions and methods for the treatment of oral infectious diseases |
BR112019010816A2 (en) * | 2016-11-28 | 2019-10-01 | Cellix Bio Private Ltd | compound of formula i, compound of formula ii, compound of formula iii, compound of formula iv, compound of formula v, pharmaceutical composition, compounds, compound of formula viii, compound of formula ix, and compound of formula x |
JP2022542403A (en) * | 2019-07-31 | 2022-10-03 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | Co-crystals of posaconazole, methods of making and using the same |
JP2021054781A (en) * | 2019-09-26 | 2021-04-08 | デボン エルエス,リミテッド | Co-crystalline efinaconazole and method for producing the same |
BR112022022795A2 (en) * | 2020-05-12 | 2022-12-13 | Cellix Bio Private Ltd | PROCESS FOR PREPARING TRIAZOLE SALTS, AND TRIAZOLE SALTS PREPARED BY THE PROCESS |
CN112999219B (en) * | 2021-03-10 | 2022-05-03 | 湖北中医药大学 | Common amorphous substance containing andrographolide, and its preparation method and pharmaceutical composition |
CN116183736B (en) * | 2022-07-25 | 2024-02-09 | 北京和合医学诊断技术股份有限公司 | LC-MS/MS analysis method for simultaneously detecting 9 antibiotics in alveolar lavage fluid |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016733A1 (en) * | 1993-01-29 | 1994-08-04 | Chiesi Farmaceutici S.P.A. | Highly soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin |
US5998413A (en) * | 1992-03-18 | 1999-12-07 | Janssen Pharmaceutica, N.V. | Itraconazole and stereoisomers |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4267179A (en) | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
GB8506792D0 (en) | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
US4916134A (en) | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
NZ223799A (en) * | 1987-03-25 | 1989-12-21 | Janssen Pharmaceutica Nv | Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions |
JP2581707B2 (en) | 1987-10-02 | 1997-02-12 | 科研製薬株式会社 | Antifungal composition |
US5006513A (en) | 1987-11-09 | 1991-04-09 | Miles Inc. | Antimycotic compositions of nikkomycin compounds and azole antimycotica |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
PH30929A (en) | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
US5414997A (en) | 1993-01-11 | 1995-05-16 | Tailer; Peter L. | Thermal lag machine |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
WO1994016700A1 (en) | 1993-01-27 | 1994-08-04 | Sepracor, Inc. | Method and composition employing (2r,4s) itraconazole |
TW349870B (en) | 1993-09-30 | 1999-01-11 | Janssen Pharmaceutica Nv | An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof |
DE69428125T2 (en) | 1993-12-21 | 2002-05-02 | Schering Corp | FUNGICIDAL TETRAHYDROFURANE |
US5661151A (en) | 1993-12-21 | 1997-08-26 | Schering Corporation | Tetrahydrofuran antifungals |
IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
KR19990001564A (en) | 1997-06-16 | 1999-01-15 | 유충식 | Azole antifungal agents with improved solubility and preparations containing them |
PT1150960E (en) | 1999-12-08 | 2005-06-30 | Pharmacia Corp | CELECOXIB POLYMORIC CRYSTALLINE FORMS |
WO2001051919A2 (en) | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
GB0015239D0 (en) | 2000-06-21 | 2000-08-16 | Biochemie Gmbh | Organic compounds |
US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
US6663897B2 (en) | 2001-02-06 | 2003-12-16 | Dsm Ip Assets B.V. | Oral itraconazole formulations and methods of making the same |
CA2363376A1 (en) * | 2001-11-16 | 2003-05-16 | Bernard Charles Sherman | Solid pharmaceutical compositions for oral administration comprising itraconazole |
US7078526B2 (en) | 2002-05-31 | 2006-07-18 | Transform Pharmaceuticals, Inc. | CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods |
AU2003213719A1 (en) | 2002-03-01 | 2003-09-16 | Regents Of The University Of Michigan | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
US7452555B2 (en) | 2003-01-21 | 2008-11-18 | S.S.C.I., Inc. | Cocrystallization |
JP2007524596A (en) * | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | Co-crystal pharmaceutical composition |
-
2003
- 2003-05-30 US US10/449,307 patent/US7078526B2/en not_active Expired - Lifetime
- 2003-05-30 AU AU2003243354A patent/AU2003243354A1/en not_active Abandoned
- 2003-05-30 WO PCT/US2003/017184 patent/WO2003101392A2/en active Application Filing
- 2003-05-30 JP JP2004508750A patent/JP2005535602A/en active Pending
- 2003-05-30 EP EP03756321A patent/EP1511490A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998413A (en) * | 1992-03-18 | 1999-12-07 | Janssen Pharmaceutica, N.V. | Itraconazole and stereoisomers |
WO1994016733A1 (en) * | 1993-01-29 | 1994-08-04 | Chiesi Farmaceutici S.P.A. | Highly soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin |
Non-Patent Citations (2)
Title |
---|
REMENAR ET AL.: "Crystal engineering of novel cocrystals of a tiazole drug with 1,4-dicarboxylic acids", J. AM. CHEM. SOC., vol. 125, June 2003 (2003-06-01), pages 8456 - 8457, XP002973472 * |
See also references of EP1511490A4 * |
Also Published As
Publication number | Publication date |
---|---|
US7078526B2 (en) | 2006-07-18 |
EP1511490A4 (en) | 2009-03-11 |
WO2003101392A2 (en) | 2003-12-11 |
AU2003243354A8 (en) | 2003-12-19 |
AU2003243354A1 (en) | 2003-12-19 |
US20040019211A1 (en) | 2004-01-29 |
EP1511490A2 (en) | 2005-03-09 |
JP2005535602A (en) | 2005-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003101392A3 (en) | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods | |
MA28334A1 (en) | PHARMACEUTICAL ANTIVIRAL COMPOSITIONS | |
WO2004069138A3 (en) | Pharmaceutical formulation | |
WO2006066914A3 (en) | Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors | |
WO2004058769A3 (en) | Triazolopyridazines as protein kinases inhibitors | |
WO2003048081A3 (en) | Glycinamides as factor xa inhibitors | |
WO2005058835A3 (en) | Methods of preparing aripiprazole crystalline forms | |
MY145148A (en) | Pharmaceutical formulation comprising an antibiotic, a triazole and a carticosteroid | |
WO2003037860A3 (en) | Purine analogs having hsp90-inhibiting activity | |
WO2003020253A3 (en) | Pharmaceutical compositions for the treatment of asthma | |
WO2004089296A3 (en) | Improved inhibitors for the soluble epoxide hydrolase | |
WO2006045119A3 (en) | Improved inhibitors for the soluble epoxide hydrolase | |
AU2003227741A1 (en) | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
WO2004026231A3 (en) | Formulation for lipophilic agents | |
WO2006068826A3 (en) | 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors | |
WO2006066913A3 (en) | Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors | |
WO2007100382A3 (en) | Orally administrable gallium compositions and method of use | |
WO2007067593A3 (en) | Self-emulsifyng formulations of cetp inhibitors | |
WO2002102793A3 (en) | Quinazolinediones as antibacterial agents | |
AU2002358676A1 (en) | Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
WO2003051300A8 (en) | Metal complexes and formulations of rifamycin analogues and uses therof | |
WO2004060347A3 (en) | Pharmaceutical propylene glycol solvate compositions | |
WO2005007117A3 (en) | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders | |
WO2004009091A8 (en) | Purine derivatives as liver x receptor agonists | |
WO2005034999A3 (en) | Composition comprising association complex of a pharmaceutical and a poloxamer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004508750 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003756321 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003756321 Country of ref document: EP |